Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19

Set Alert for Coronavirus COVID-19

Merck KGaA Fertility Business And Mavenclad Held Back By COVID-19 But Recovery Signs

Merck KGaA’s pharmaceutical sales were adversely affected by the COVID-19 pandemic in the second quarter, but the Process Solutions part of its life sciences division, products from which support vaccine developers, had a good quarter, and a potential dual Toll-like receptor inhibitor, M5049, entered Phase II.

Coronavirus Update: Gilead To Meet Global Remdesivir Demand By October

Ramp-up is possible thanks to increased internal capacity and network of voluntary licensing partners including Mylan, Cipla and Dr Reddy's.

Novavax-Serum Institute Seal Win-Win Deal For COVID-19 Vaccine

Novavax has granted Serum Institute rights to develop, manufacture and commercialize its COVID-19 vaccine candidate in selected regions, in another endorsement of the Indian group's capabilities. The agreement, which expands on an earlier association, gives Serum exclusive marketing rights in India until the deal ends and non-exclusive rights for developing countries to the end of the pandemic, with the US firm getting half of net revenue.

Coronavirus Update: BioNTech And Fosun Launch Vaccine Trial In China

The study is designed to support the regulatory approval process in China and confirm that the safety and immunogenicity profile observed in German and US trials is comparable to that of Chinese participants, according to BioNTech.

Divided House On Challenge Trials For COVID-19 Vaccines But Collaboration Goals Unite

High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.

Moderna Sets High Coronavirus Vaccine Pricing Bar In Small, Early Deals

The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.

Regeneron Pipeline Progresses On Several Fronts Despite COVID-19 Focus

Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.

Novavax’s COVID-19 Vaccine Boost From First Phase I Data

A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.

Virus-Hit Astellas Cuts Forecast

Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.

Bayer Q2 Pharma Sales Ravaged By COVID-19

Turnover at the German group's pharma unit has been hit harder than forecast by the coronavirus pandemic and hefty price cuts linked to China's drug procurement policy but Bayer remains upbeat.

Coronavirus Update: Lilly Initiates 2,400-Patient Nursing Home Trial

Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.

Coronavirus Update: Russia Plans First Vaccinations In October

Concern and skepticism about Russia's rapid vaccine roll out. Meanwhile Japan is latest to reach deal with Pfizer/BioNTech.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales

The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus. 

Sanofi/GSK Working With The US To Increase COVID-19 Vaccine Capacity

The $2.1bn investment under the US’ Operation Warp Speed will fund development, scale-up of US manufacturing and the first 100 million doses. 

Coronavirus Update: J&J’s Single Dose Stands Out From COVID Vaccine Crowd

J&J is a few months behind companies like Moderna, Pfizer and AstraZeneca in the race to develop a vaccine, but a safe and effective single dose immunization would be a game changer.

UsernamePublicRestriction

Register